Cargando…

Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse

Mantle cell lymphoma (MCL) is an aggressive, difficult to treat subtype of lymphoma, resulting in relapses and poor outcomes. Novel agents such as Bruton tyrosine kinase (BTK) inhibitors have been studied in the treatment of relapsed/refractory (R/R) MCL. BTK inhibitor ibrutinib, in particular, has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Timothy S., Burkart, Madelyn, Behdad, Amir, Savas, Hatice, Karmali, Reem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106524/ https://www.ncbi.nlm.nih.gov/pubmed/35571529 http://dx.doi.org/10.1155/2022/1930546

Ejemplares similares

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Blastoid mantle cell lymphoma: cutaneous infiltration()()
por: de Ré, Mariana Righetto, et al.
Publicado: (2021)

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
por: Qualls, David, et al.
Publicado: (2022)

Blastoid mantle cell lymphoma in a patient with chronic myeloproliferative neoplasia
por: Soares, Thamiris Silva, et al.
Publicado: (2023)

Fatal Blastoid Variant Mantle Cell Lymphoma in a Patient with Sjögren's Syndrome
por: Bonilla-Abadía, Fabio, et al.
Publicado: (2013)

Blastoid mantle cell lymphoma presenting as acute leukemia: a case report
por: Dongre, Amol, et al.
Publicado: (2021)

Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features
por: Khanlari, Mahsa, et al.
Publicado: (2023)

Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
por: Mair, Anna, et al.
Publicado: (2021)

A Push to Consider Mantle Cell Lymphoma in Adults with Leukemia/Lymphoma with Blastoid Morphology
por: Arinze, Nkechi, et al.
Publicado: (2023)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Blastoid Variant Mantle Cell Lymphoma with Complex Karyotype Including 11q Duplication
por: Özer, Özge, et al.
Publicado: (2014)

Cutaneous Involvement as a First Sign of CD5(-) Blastoid Mantle Cell Lymphoma
por: Zekey, Emre, et al.
Publicado: (2023)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
por: Wang, Michael, et al.
Publicado: (2021)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist
por: Patel, Vishal, et al.
Publicado: (2020)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses
por: Zanelli, Magda, et al.
Publicado: (2023)

Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review
por: Rich, Jessica D., et al.
Publicado: (2019)

CD5-negative Blastoid Variant Mantle Cell Lymphoma with Complex CCND1/IGH and MYC Aberrations
por: Seok, Yoonmi, et al.
Publicado: (2012)

Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
por: Sun, Kai, et al.
Publicado: (2018)

Current overview and treatment of mantle cell lymphoma
por: Schieber, Michael, et al.
Publicado: (2018)

P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Yazji, S., et al.
Publicado: (2022)

Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2019)

Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review
por: Mannina, Donato, et al.
Publicado: (2017)

Mantle cell lymphoma, blastoid variant, diagnosed on the basis of cytomorphology and flow cytometric immunophenotyping of the lymph node aspirate and peripheral blood.
por: Lee, Mi-Ja, et al.
Publicado: (2002)

Bi-allelic amplification of ATM gene in blastoid variant of mantle cell lymphoma: a novel mechanism of inactivation due to chromoanagenesis?
por: Ortega, Veronica, et al.
Publicado: (2021)

A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
por: Wallace, Natalie, et al.
Publicado: (2016)

Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma
por: Hansen, Marcus Høy, et al.
Publicado: (2021)

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
por: Zhang, Yuchen, et al.
Publicado: (2022)

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
por: Galinier, Aliénor, et al.
Publicado: (2017)

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2017)

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2021)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma
por: Broccoli, Alessandro, et al.
Publicado: (2018)

Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
por: Yi, Jun Ho, et al.
Publicado: (2021)

Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: McNally, Gretchen Anne, et al.
Publicado: (2015)

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma
por: Fuhr, Viktoria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9ab4ngv6lec160fokff6mm8vgp